

To protect patient privacy,  
the PPB Registry will strip  
identifying information from  
all documents.

**Pleuropulmonary Blastoma Registry**  
**Type I PPB Treatment Roadmap**  
**Course 4 of 4**

Pt. Name: \_\_\_\_\_  
MR #: \_\_\_\_\_  
DOB: \_\_\_\_\_

Dosing rules: use current age and size at start of each course  
Age \_\_\_\_\_ mos Ht. \_\_\_\_\_ cm Wt. \_\_\_\_\_ kg BSA \_\_\_\_\_ m<sup>2</sup>

| Date Due | Date Given | Week | VCR<br>_____mg | DACT**<br>_____mg | CPM<br>_____mg | MESNA<br>_____mg | G*<br>_____mcg |
|----------|------------|------|----------------|-------------------|----------------|------------------|----------------|
| _____    | _____      | 36   | VCR _____      | DACT** _____      | CPM _____      | MESNA _____      | G* _____       |
| _____    | _____      | 37   | VCR _____      |                   |                |                  | x 10 days      |
| _____    | _____      | 38   | VCR _____      |                   |                |                  |                |
| _____    | _____      | 39   | VCR _____      | DACT** _____      | CPM _____      | MESNA _____      | G* _____       |
| _____    | _____      | 40   | VCR _____      |                   |                |                  | x 10 days      |
| _____    | _____      | 41   | VCR _____      |                   |                |                  |                |
| _____    | _____      | 42   | VCR _____      | DACT** _____      | CPM _____      | MESNA _____      | G* _____       |
| _____    | _____      | 43   | VCR _____      |                   |                |                  | x 10 days      |
| _____    | _____      | 44   | VCR _____      |                   |                |                  |                |
| _____    | _____      | 45   |                | DACT** _____      |                |                  |                |
| _____    | _____      | 46   |                |                   |                |                  |                |
| _____    | _____      | 47   |                |                   |                |                  |                |

Begin Follow up

**Dosages for patients ≥ 3 yrs:**

|                               |             |  |
|-------------------------------|-------------|--|
| <b>Vincristine (VCR)</b>      | <b>IV</b>   | 1.5 mg/m <sup>2</sup> IV push Day 0 of weeks 36 - 44 (Max. dose 2 mg).<br>0.045mg/kg Day 0 of weeks 36, 39, 42, 45 (Max dose 2.5 mg).  |
| <b>**Actinomycin D (DACT)</b> | <b>IV</b>   | **OMIT DACT if radiation therapy is used during this course.   |
| <b>Cyclophosphamide (CPM)</b> | <b>IV</b>   | 1.2 gm/m <sup>2</sup> /dose IV as 1 hr infusion with IV fluids and MESNA, day 0 of weeks 36, 39, and 42.   |
| <b>Mesna</b>                  | <b>IV</b>   | 240 mg/m <sup>2</sup> /dose x 3 doses: dose 1 with CPM over 1 hour; doses 2 & 3 IV push over 3 - 5 min. at hours 4 and 8.  |
| <b>*G-CSF (G)</b>             | <b>SubQ</b> | 5 mcg/kg/day s.c. starting day 1; 24 hrs after VAC, continuing daily for 10 days or until nadir has passed and ANC > 2000/μl.<br>*Use only for chemo delay or if chemo doses are modified for heme toxicity/significant bone marrow suppression. |

**Comments**

(Entries must be dated)

**Dose modifications for children  
≥ 12 months but < 3 yrs of age:**

|                |                 |
|----------------|-----------------|
| <b>VCR:</b>    | use 0.05 mg/kg  |
| <b>**DACT:</b> | use 0.045 mg/kg |
| <b>CPM:</b>    | use 40 mg/kg    |
| <b>Mesna:</b>  | use 8 mg/kg     |
| <b>*G-CSF:</b> | Use 5 mcg/kg    |

**Dose modifications for children < 12 months of  
age:**

|                |                 |
|----------------|-----------------|
| <b>VCR:</b>    | use 0.025 mg/kg |
| <b>**DACT:</b> | use 0.025 mg/kg |
| <b>CPM:</b>    | use 40 mg/kg    |
| <b>Mesna:</b>  | use 8 mg/kg     |
| <b>*G-CSF:</b> | Use 5 mcg/kg    |